Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
about
Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to dateTafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparumDrugs in Development for Malaria.Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry
P2860
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@ast
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@en
type
label
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@ast
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@en
prefLabel
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@ast
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@en
P2093
P2860
P356
P1476
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
@en
P2093
Babu L Tekwani
Brandon S Pybus
Brittney M J Potter
Bryan Smith
Chau Vuong
Christina K Nolan
Dehui Duan
Gregory A Reichard
Jason C Sousa
Jing Zhang
P2860
P304
P356
10.1128/AAC.00343-15
P407
P577
2015-04-13T00:00:00Z